Background {#Sec1}
==========

As the top ranked malignancy of the urinary system, bladder cancer (BCa) incidence data in the US shows an estimated 79,030 (8th among all sites) new cases and 16,870 (8th among all sites) deaths in 2017 \[[@CR1]\]. Unfortunately, 10--15% of BCa patients already have metastasis at initial diagnosis and 15--30% high-grade BCa will eventually progress to advanced disease and lead to poor prognosis \[[@CR2]\].

Despite an initial response to chemotherapy, patients with non-organ-confined disease fail to attain satisfactory survival \[[@CR3]\]. Since no optimally effective chemotherapeutic modality has been found, patients with NOC disease can barely survive for more than 3--6 months \[[@CR4]\]. According to a previous population-based study of the SEER database, only 4.1% (76/1862) BCa patients had brain metastases in a cohort of 1862 patients with metastatic sites \[[@CR5]\]. Given the rarity of brain metastases at presentation, currently, there is no randomized phase II or III clinical trials exploring outcomes of this group. The survival prognosis of this subgroup calls for significant melioration when compared to those with cerebral metastasis from other malignancies \[[@CR6]\].

Some reports have claimed that stereotactic radiosurgery and whole-brain irradiation can be a useful alternative approach for patients with brain metastasis in certain malignancies \[[@CR7], [@CR8]\]; however, suitable treatment for BCa patients with brain metastases remains unclear. A study conducted in 2002 in Cleveland retrospectively analyzed 16 BCa patients with brain metastases and suggested more aggressive treatment rather than radiation therapy alone \[[@CR9]\]. However, the cohort was too small to extract robust clinical traits. In 2010, Fokas et al. found no significant difference in survival after comparing radiotherapy alone with radiotherapy plus surgery in 62 patients with brain metastases from BCa \[[@CR10]\]. Therefore, reconsideration of current medical strategies is indispensable, since the role of surgeries of the primary tumor or radiotherapy of brain lesions in the treatment of metastatic BCa is still obscure.

Although previous studies have identified several prognostic factors of poor outcome in advanced BCa, such as the presence of visceral metastasis, anemia, and C-reactive protein (CRP) \[[@CR3], [@CR11], [@CR12]\], it remains unknown whether they could be applied to the clinical assessment. Currently, prognostic nomograms are widely applied as prognostic devices in oncologic medicine. With the ability to incorporate clinical characteristics to generate individual probabilities of clinical events, nomograms can aid clinical decisions and facilitate our drive towards personalized medicine \[[@CR13]\]. The purpose of our study was to create a nomogram predicting overall survival (OS) of BCa patients with brain metastasis and evaluate suitable therapeutic modalities for this cohort.

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

The National Cancer Database (NCDB) was queried for patients initially diagnosed with histological confirmed BCa (topographical code C67, International Classification of Diseases for Oncology, 3rd edition) between 2004 and 2015. Patients with brain metastatic disease at the time of presentation were selected for the analysis.

Baseline medical traits (including age; sex, race; pathological grade; tumor histology, lymph node vascular invasion, and clinical stage \[TNM\] of the American Joint Committee on Cancer; surgical statuses of the primary and metastatic sites; chemotherapy; radiation therapy; and palliative care) were derived from medical records (Table [1](#Tab1){ref-type="table"}). Other inclusion criteria were as follows: age \> 18 years; BCa as the primary cancer diagnosis; brain metastasis; other distant metastatic sites including bone, liver, lung, and distant lymph node involvement; active follow-up; and patients with \> 30 days of survival. Patients without sufficient information about distant metastatic sites or survival data were excluded. No detailed data were available regarding the specific types of chemotherapy or hormonal therapy or palliative care agents. Finally, we included 234 patients with the above-mentioned criteria. We used a computer-generated random seed to assign 169 of these patients to the training set, and 65 patients to the internal testing set for subsequent analysis. Work of flow is displayed in Fig. [1](#Fig1){ref-type="fig"}.Table 1Description of clinical characteristics and their valuesClinical variablesDescriptionValuesAgeAge of the patient at diagnosis\< 65 years or ≥ 65 yearsSexThe gender of the patientMale or femaleRaceThe primary race of the personWhite, black or othersGradeDescribes the tumor's resemblance to normal tissue (coded according to ICD-O-3)Well differentiated, poorly differentiated or UnknownTumor_StageNCDB analytic stage identifies the clinically or pathologically determined size and/or extension of the primary tumor (cT) as defined by the American Joint Committee on Cancer (AJCC)High (Stage III, IV) or low (Stage I, II)Lymph_nodesIdentifies the clinically-determined absence or presence of regional lymph node metastasis and describes the corresponding extent as defined by the American Joint Committee on Cancer (AJCC)Yes, no or unknownHistologyIndicate the pathological histology of tumor cells (coded according to ICD-O-3)Transitional cell carcinoma, papillary urothelial carcinoma, small cell carcinoma or othersLymph_Vas_invasionIndicate the presence or absence of tumor cells in lymphatic channels (other than lymph nodes) or blood vessels within the primary tumor as noted microscopically by the pathologistYes, no or unknownMet_BoneIndicate the presence of distant involvement of bone at the time of diagnosisYes or noMet_LiverIndicate the presence of distant involvement of liver at the time of diagnosisYes or noMet_LungIndicate the presence of distant involvement of lung at the time of diagnosisYes or noSurgery_PrimaryRecords the surgical procedure and approach performed to the primary siteMinimal invasive surgery, non-minimal invasive surgery or no surgeryChemotherapyRecords of chemotherapy administrated as first course treatmentYes or noRadiation_TherapyAnatomic target volume is directed at tumors lying within the substance of brain or its meningesYes or noPaliative_CareAny care provided an effort to palliate or alleviate symptomsYes or noBrain_Confined_MetIndicate the presence of distant involvement of brain only or brian combined with other organs at the time of diagnosisBrain confined or non-brain confinedCDCC_ScoreCharlson/Deyo Score, a weighted score derived from the sum of the scores for each of the comorbid conditions listed in the Charlson Comorbidity Score Mapping Table (source <http://dx.doi.org/10.17632/nn6y58v8vv.1#file-a72735e9-15b5-4a10-aef5-deddad2463e8>)0--3Surgery_MetRecords the surgical removal of distant lymph nodes or other tissues or organs beyond the primary siteYes or noFig. 1Flowchart of the analysis

Compliance with ethical standards {#Sec4}
---------------------------------

The NCDB is a hospital-based registry of cases treated at American College of Surgeons Commission on Cancer accredited cancer programs. Extraction of data from the NCDB did not require extra informed consent. All the data were downloaded at the Sidney Kimmel Cancer Center of Thomas Jefferson University.

Statistical analysis {#Sec5}
--------------------

For feature selection, we used the least absolute shrinkage and selection operator (LASSO) method, which is a machine learning method suitable for the reduction of high-dimensional data \[[@CR14]\]. Eighteen variables were used to select the most useful predictive features from the primary data set. The LASSO regression model analysis was performed using the *glmnet* package of R (R Foundation for Statistical Computing, Vienna, Austria).

Univariate and multivariate Cox regression analysis were performed to explore the independent prognostic factors via the *survival* package of R. The Schoenfeld residuals method was applied to test the proportional hazards assumption for the Cox regression model fit. Each regression coefficient of selected variables was converted to a 0 to 100 scale proportion according to its contribution. These points were added across enrolled variables to generate total points, which were then transformed to predicted probabilities. For clinical use, the predictive performance of the nomogram was measured via time-dependent receiver operating characteristic (ROC) analysis with area under the curve (AUC) values. Calibration was employed with bootstrapping to decrease the bias of over-fitting. The *x*-axis represented the prediction calculated using the nomogram, and the *y*-axis the actual risk odds for the individual. The 45-degree line represented an ideal performance of the nomogram, in which the predicted outcome perfectly corresponded with the actual outcome. The model that incorporated the above independent predictors was developed and presented as the nomogram. Nomogram and calibration plots were obtained using the *rms* and *nomogramEx* packages of R.

Survival analysis was performed using the Kaplan--Meier method to probe the correlation between variables and OS, and the log-rank test was performed to compare survival variance in different groups. Decision curve analysis were performed to compare with the current AJCC TNM staging system. All statistical tests and analyses were performed in R software version 3.5.1. Statistical significance was set at \< 0.05.

Results {#Sec6}
=======

Clinicopathologic characteristics {#Sec7}
---------------------------------

During the study procedure, 268 consecutive BCa patients with brain-involvement were identified from the NCDB. Of these, 234 patients with brain metastasis in accordance with the inclusion criteria were enrolled, and 169 and 65 patients were randomly divided into the training and internal validation cohorts, respectively. The clinicopathologic characteristics and baseline data in the primary and validation cohorts are provided in Table [2](#Tab2){ref-type="table"}. The median follow-up time was 3.38 (range: 1.08--61.21) months.Table 2Baseline characteristics and distribution of risk stratification of patients in the training and validation cohortsCharacteristicsTraining set (%)Internal testing set (%)Number of casesHigh riskLow riskNumber of casesHigh riskLow riskAge \< 65 years71 (42)32 (18.9)39 (23.1)22 (33.8)11 (16.9)11 (16.9) ≥ 65 years98 (58)49 (29)49 (29)43 (66.2)21 (32.3)22 (33.8)Sex Male128 (75.7)63 (37.3)65 (38.5)47 (72.3)19 (29.2)28 (43.1) Female41 (24.3)18 (10.7)23 (13.6)18 (27.7)13 (20)5 (7.7)Race White148 (87.6)70 (41.4)78 (46.2)59 (90.8)29 (44.6)30 (46.2) Black16 (9.5)8 (4.7)8 (4.7)4 (6.2)3 (4.6)1 (1.5) Others5 (3)3 (1.8)2 (1.2)2 (3.1)0 (0)2 (3.1)Grade Well differentiated14 (8.3)10 (5.9)4 (2.4)1 (1.5)0 (0)1 (1.5) Poorly differentiated96 (56.8)39 (23.1)57 (33.7)39 (60)19 (29.2)20 (30.8) Unknown59 (34.9)32 (18.9)27 (16)25 (38.5)13 (20)12 (18.5)Histology TCC94 (55.6)49 (29)45 (26.6)38 (58.5)17 (26.2)21 (32.3) PUC42 (24.9)15 (8.9)27 (16)8 (12.3)5 (7.7)3 (4.6) SCC10 (5.9)3 (1.8)7 (4.1)7 (10.8)2 (3.1)5 (7.7) Others23 (13.6)14 (8.3)9 (5.3)12 (18.5)8 (12.3)4 (6.2)Tumor_Stage Low13 (7.7)7 (4.1)6 (3.6)4 (6.2)2 (3.1)2 (3.1) High156 (92.3)74 (43.8)82 (48.5)61 (93.8)30 (46.2)31 (47.7)Lymph_nodes No87 (51.5)39 (23.1)48 (28.4)33 (50.8)16 (24.6)17 (26.2) Yes36 (21.3)14 (8.3)22 (13)17 (26.2)9 (13.8)8 (12.3) Unknown46 (27.2)28 (16.6)18 (10.7)15 (23.1)7 (10.8)8 (12.3)Lymph_Vas_Invasion No31 (18.3)12 (7.1)19 (11.2)12 (18.5)5 (7.7)7 (10.8) Yes29 (17.2)13 (7.7)16 (9.5)6 (9.2)3 (4.6)3 (4.6) Unknown109 (64.5)56 (33.1)53 (31.4)47 (72.3)24 (36.9)23 (35.4)Met_Bone No112 (66.3)47 (27.8)65 (38.5)44 (67.7)26 (40)18 (27.7) Yes57 (33.7)34 (20.1)23 (13.6)21 (32.3)6 (9.2)15 (23.1)Met_Liver No129 (76.3)61 (36.1)68 (40.2)50 (76.9)25 (38.5)25 (38.5) Yes40 (23.7)20 (11.8)20 (11.8)15 (23.1)7 (10.8)8 (12.3)Met_Lung No100 (59.2)40 (23.7)60 (35.5)34 (52.3)16 (24.6)18 (27.7) Yes69 (40.8)41 (24.3)28 (16.6)31 (47.7)16 (24.6)15 (23.1)Surgery_Primary Minimal invasive65 (38.5)27 (16)38 (22.5)31 (47.7)19 (29.2)12 (18.5) No83 (49.1)48 (28.4)35 (20.7)29 (44.6)9 (13.8)20 (30.8) Non-minimal invasive21 (12.4)6 (3.6)15 (8.9)5 (7.7)4 (6.2)1 (1.5)Chemotherapy No97 (57.4)77 (45.6)20 (11.8)36 (55.4)28 (43.1)8 (12.3) Yes72 (42.6)4 (2.4)68 (40.2)29 (44.6)4 (6.2)25 (38.5)Radiation_Therapy No89 (52.7)50 (29.6)39 (23.1)38 (58.5)14 (21.5)24 (36.9) Yes80 (47.3)31 (18.3)49 (29)27 (41.5)18 (27.7)9 (13.8)Palliative_Care No122 (72.2)62 (36.7)60 (35.5)47 (72.3)21 (32.3)26 (40) Yes47 (27.8)19 (11.2)28 (16.6)18 (27.7)11 (16.9)7 (10.8)Brain_Confined_Met No67 (39.6)24 (14.2)43 (25.4)22 (33.8)13 (20)9 (13.8) Yes102 (60.4)57 (33.7)45 (26.6)43 (66.2)19 (29.2)24 (36.9)CDCC_Score 0116 (68.6)50 (29.6)66 (39.1)46 (70.8)23 (35.4)23 (35.4) 137 (21.9)19 (11.2)18 (10.7)12 (18.5)8 (12.3)4 (6.2) 210 (5.9)7 (4.1)3 (1.8)5 (7.7)1 (1.5)4 (6.2) 36 (3.6)5 (3)1 (0.6)2 (3.1)0 (0)2 (3.1)Surgery_Met No144 (85.2)72 (42.6)72 (42.6)55 (84.6)25 (38.5)30 (46.2) Yes25 (14.8)9 (5.3)16 (9.5)10 (15.4)7 (10.8)3 (4.6)*TCC* transitional cell carcinoma, *PUC* papillary urothelial carcinoma, *SCC* small cell carcinoma

Feature selection via LASSO {#Sec8}
---------------------------

LASSO with tenfold cross-validation generated 7 variables out of 18 features: Grade, Surgery_Primary, Chemotherapy, Radiation_Therapy, Paliative_Care, Brain_Confined_Met, and CDCC_Score (Fig. [2](#Fig2){ref-type="fig"}a, b). The results of the univariate and multivariate Cox regression of the primary cohort are recorded in Table [3](#Tab3){ref-type="table"}. Surgery_Primary, Chemotherapy, Radiation_Therapy, Paliative_Care, Brain_Confined_Met, and CDCC_Score were chosen for further analysis (apart from Radiation_Therapy, all other variables were independent prognostic factors in the LASSO Cox model; the reason for including this variable will be explained in "[Discussion](#Sec10){ref-type="sec"}"). P values for Schoenfeld residuals method were all \> 0.05 which fitted the proportional hazards assumption for the Cox model (Additional file [1](#MOESM1){ref-type="media"}: Fig. S1).Fig. 2Clinical trait selection via the least absolute shrinkage and selection operator (LASSO) cox regression model. **a** Tenfold cross-validated error (first vertical line equals the minimum error (lambda = 0.066), whereas the second vertical line shows the cross-validated error within 1 standard error of the minimum). **b** The profile of coefficients in the model at varying levels of penalization plotted against the log (lambda) sequenceTable 3Univariate and multivariate Cox regression analysis of BCa patients based on clinicopathological characteristics derived from NCDB data in the training cohortCharacteristicsUnivariate analysis HR (95% CI)P valueMultivariate analysis HR (95% CI)P valueAge (\< 65 years vs. ≥ 65 years)1.117 (0.819--1.525)0.481.032 (0.705--1.511)0.87Sex (male vs. female)0.861 (0.602--1.233)0.421.166 (0.756--1.797)0.49Race White vs. black0.871 (0.509--1.489)0.610.956 (0.523--1.747)0.88 White vs. others0.889 (0.363--2.174)0.800.524 (0.197--1.39)0.19Grade Well differentiated vs. poorly differentiated0.896 (0.511--1.574)0.701.317 (0.653--2.656)0.44 Well differentiated vs. unknown1.144 (0.636--2.057)0.651.634 (0.753--3.546)0.21Histology TCC vs. PUC0.851 (0.588--1.232)0.391.181 (0.738--1.89)0.49 TCC vs. SCC1.083 (0.563--2.087)0.811.495 (0.714--3.13)0.29 TCC vs. others0.916 (0.578--1.45)0.710.629 (0.363--1.09)0.10Lymph_nodes No vs. yes0.835 (0.564--1.234)0.370.808 (0.51--1.28)0.36 No vs. unknown0.985 (0.682--1.422)0.930.761 (0.485--1.196)0.24Lymph_Vas_Invasion No vs. yes1.098 (0.658--1.832)0.721.494 (0.816--2.736)0.19 No vs. unknown1.291 (0.859--1.94)0.221.269 (0.764--2.107)0.36Tumor_Stage (low vs. high)1.247 (0.704--2.21)0.451.089 (0.536--2.211)0.81Met_Bone (no vs. yes)1.026 (0.742--1.42)0.880.61 (0.374--0.997)0.05Met_Liver (no vs. yes)0.978 (0.683--1.4)0.901.223 (0.761--1.966)0.41Met_Lung (no vs. yes)1.317 (0.962--1.802)0.090.878 (0.525--1.469)0.62Surgery primary Minimal invasive surgery vs. no surgery1.44 (1.031--2.011)0.032.529 (1.609--3.975)\< 0.001 Minimal invasive surgery vs. non-minimal invasive0.923 (0.558--1.525)0.751.253 (0.672--2.334)0.48Chemotherapy (no vs. yes)0.353 (0.25--0.498)\< 0.0010.213 (0.137--0.332)\< 0.001Radiation_Therapy (no vs. yes)0.723 (0.53--0.986)0.040.708 (0.486--1.031)0.07Palliative_Care (no vs. yes)0.922 (0.651--1.305)0.650.631 (0.413--0.964)0.03Brain_Confined_Met (non--brain confined vs. brain confined)1.248 (0.911--1.71)0.172.229 (1.144--4.345)0.02CDCC_Score 0 vs. 11.29 (0.886--1.878)0.181.439 (0.929--2.23)0.10 0 vs. 21.529 (0.798--2.926)0.201.865 (0.861--4.038)0.11 0 vs. 32.14 (0.932--4.91)0.072.545 (1.035--6.256)0.04Surgery_Met (yes vs. no)0.9 (0.58--1.396)0.640.918 (0.546--1.542)0.75

Development and validation of the prognostic nomogram {#Sec9}
-----------------------------------------------------

The prognostic nomogram that integrated all selected factors for OS in the primary cohort is shown in Fig. [3](#Fig3){ref-type="fig"}. We then derived a formula to calculate the risk score for odds of death for every patient based on their individual status of the selected variables above. To take one patient for example (purple track in Fig. [3](#Fig3){ref-type="fig"}), basing on the selected features, the total points adds up to 323 and thus the corresponding 0.5- and 1-year death probabilities are 0.647 and 0.9 respectively. The equation of each variable and computational formula is presented in Table [4](#Tab4){ref-type="table"}. We further stratified those patients with an average or higher-than-average risk score into the high risk group and those with lower-than-average risk score into the low risk group (Table [1](#Tab1){ref-type="table"}). In terms of 0.5- and 1-year OS of the training set, our six-clinical variable-based classifier demonstrated favorable discrimination with AUC values of 0.823 (95% confidence interval \[CI\] 0.758--0.889, P \< 0.001) and 0.854 (95% CI 0.785--0.924, P \< 0.001), respectively (Fig. [4](#Fig4){ref-type="fig"}a). The internal-bootstrapped calibration plot for the probability of survival at 0.5 or 1 year after surgery showed an optimal agreement between prediction by nomogram and actual observation (Fig. [4](#Fig4){ref-type="fig"}b, c). In the validation cohort, the nomogram displayed similar AUC values of 0.838 (95% CI 0.738--0.937, P \< 0.001) and 0.809 (95% CI 0.680--0.939, P \< 0.001) for the estimation of survival (Fig. [4](#Fig4){ref-type="fig"}d). There was also a well-behaved calibration curve for the survival estimation (Fig. [4](#Fig4){ref-type="fig"}e, f).Fig. 3Nomogram to estimate the risk and predict the survival of BCa patients with brain metastasis. Bars in blue display the distribution of patients in the training cohort. To calculate the total points of a specific patient, locate the value of each variable on the top point axis, add the points from all of the variables, and draw a vertical line from the total point axis to determine the 0.5 and 1 year death probabilities at the lower line of the nomogram. Purple track provided an example for the calculation of total-points-to-outcome (\*P \< 0.05, \*\*P \< 0.01, \*\*\*P \< 0.001)Table 4The risk point of each variable and computational formula of OSClinical variablesValuesRisk pointsRadiation_TherapyNo56Yes42Palliative_CareNo56Yes40Brain_Confined_MetNon-brain confined73Brain confined56CDCC_Score1562743764100Surgery_PrimaryNo90Minimal invasive56Non-minimal invasive53ChemotherapyNo56Yes00.5-Year Survival = 7.5e−08 \* points \^3 − 2.7837e−05 \* points \^2 − 0.001082565 \* points + 0.8155189121-Year survival = 1.21e−07 \* points \^3 − 2.3544e−05 \* points \^2 − 0.003130703 \* points + 0.651899934Fig. 4Time-dependent ROC curves comparing the prognostic accuracy of nomogram in BCa patients with metastatic brain lesions in the training cohort (**a**) and validation set (**d**). Validity of the predictive performance of the nomogram in the training cohort (**b**, **c**) and validation set (**e**, **f**). Nomogram-predicted probability of overall survival is plotted on the *x*-axis; actual overall survival is plotted on the *y*-axis. *ROC* receiver operator characteristic, *AUC* area under the curve

Kaplan--Meier survival analysis yielded a significant difference in survival between the training cohort and validation set. The median survival of the High and Low risk groups were 1.91 and 5.09 months in the training cohort (Fig. [5](#Fig5){ref-type="fig"}a) and 1.68 and 8.05 months in the validation set (Fig. [5](#Fig5){ref-type="fig"}b), respectively (both P \< 0.0001).Fig. 5Kaplan--Meier survival analysis for all patients according to our classifier stratified by clinicopathological risk factors. Survival curves show the overall survival of high risk (blue) and low risk (green) groups between the training cohort (**a**) and validation set (**b**). Confidence interval band and risk table are also added

Moreover, the decision curve analysis demonstrated that when the threshold probability was greater than 0.4, the nomogram presented more net benefit than TNM system in terms of OS prediction (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Decision curve analysis for OS. Black line: all victims dead. Gray line: none victims dead. Black dashed line: model of the nomogram. Red dashed line: staging system of TNM

Discussion {#Sec10}
==========

In this study, we developed and validated a novel prognostic tool based on six clinical variables to improve the prediction of OS for patients with confirmed BCa with metastatic brain lesions. Our results showed that this tool can well categorize patients into high-risk and low-risk groups with large differences in OS.

Generally, in our research, prognostic factors are closely related to the choices of treatment modalities, as well as the comorbidities and metastatic conditions of the patient. Known as the best method of determining comorbidity conditions, higher Charlson/Deyo Score (CDCC_Score) is reported as a poor prognostic factor for overall mortality and cancer-specific mortality in metastatic BCa \[[@CR15]\], consistent with our findings. In a previous study, multisite metastasis was found to be able to independently predict worse OS compared with single metastatic sites in BCa patients \[[@CR5]\]. Our results are in line with the study above since brain-confined metastatic disease was related with better survival.

Treatment for the metastatic group is not beyond dispute. Our study included 4 treatment variables: Surgery_Primary, Surgery_Met, Chemotherapy, Paliative_Care and Radiation_Therapy.

A previous study indicated that surgical management of the primary BCa might contribute to long-term disease-free survival in selected patients \[[@CR16]\]. Chen et al. also suggested that surgical management of the primary BCa might improve OS outcomes among patients \[[@CR17]\]. Our study uncovered that brain metastatic BCa patients can still benefit from surgical operation of the primary site via minimal invasive surgery or otherwise. As for surgeries of the metastatic site, limited conclusions could be drawn for the lack of unanimous reporting elements and resection of solitary lung metastasis may result in OS improvement when integrated with chemotherapy \[[@CR18]\]. As shown in the nomogram, though resistance may easily show up, chemotherapy still exerts maximal survival benefit for brain-metastatic BCa patients, which correlates to the first-line treatment of the European Association of Urology guidelines \[[@CR19]\]. Given that more than half of patients with metastatic urothelial cancer are unfit for cisplatin-based chemotherapy, the choice of chemotherapy combination will have to depend on the health condition of patients. Consensus from an international survey among urologic experts was reached to define patients unfit for cisplatin-based chemotherapy, which was as follows: performance score \> 1, glomerular filtration rate ≤ 60 ml/min/1.73 m^2^, grade 2 audiometric loss and peripheral neuropathy, and New York Heart Association class III heart failure \[[@CR20], [@CR21]\]. Palliative care is defined as any procedures to alleviate symptoms distinguishable from the same modality used for curative intent, which may include surgery, radiation therapy, systemic therapy, and/or other pain management drugs. Advanced BCa can be associated with problems like ureteral obstruction, persistent bleeding, pain, and/or voiding complaints; palliative care may prolong life expectancy in these patients \[[@CR22]\]. The variable Radiation_Therapy was fitted into the analysis because although the P value 0.07 slightly surpassed 0.05 in the multivariate Cox model, it was 0.04 in the univariate analysis. Moreover, for brain metastatic cancer, conventional fractionated whole brain radiotherapy is still frequently used as a standard therapy \[[@CR23]\]; thus, we included it in the prognostic nomogram for clinical consideration.

To the best of our knowledge, this is the largest cohort study exploring the prognostic significance of BCa with brain metastasis and the effect of various treatments on patients' prognoses; however, several limitations are still noteworthy. For example, information regarding metastasectomy for specific metastatic sites was incomplete. In addition, there was a lack of details and sequences concerning chemotherapy, endocrine therapy, immunological treatment, and radiation therapy. As a retrospective study population from different medical facilities, some baseline characteristics may be non-uniform and external validation cohorts are needed to confirm the predictive accuracy of the nomogram.

Conclusion {#Sec11}
==========

By combining six clinical factors of brain-metastatic BCa patients, we constructed a prognostic nomogram. The model provides an optimal estimation of OS and reference for suitable treatments in BCa patients with brain metastasis.

Supplementary information
=========================

 {#Sec12}

**Additional file 1: Fig. S1.** The graphical verification of proportional hazards assumption for the Cox regression model.
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